绿激光前列腺汽化术治疗围术期口服抗凝药患者疗效与安全性的Meta分析

doi:10.19558/j.cnki.10-1020/r.2021.03.010

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1535 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的：通过对相关对照研究进行Meta分析,评估绿激光前列腺汽化术治疗围术期口服抗凝药患者的疗效与安全性。方法：通过检索PubMed、Medline、Embase、Cochrane Library、万方数据库、中国知网数据库进行检索。使用NOS文献质量评价表对纳入文献进行质量评价。统计分析两组之间在手术时间、留置导尿管时间、住院时间、Q_max、IPSS和剩余尿等6项指标的数据。使用Revman 5.3软件进行统计学分析。结果：最终纳入7篇文献,共包含993名患者。两组患者在前列腺体积、Q_max、IPSS评分和剩余尿方面比较均无统计学差异。围术期口服抗凝药组较围术期未口服抗凝药组手术时间长,但差异无统计学意义。在术后3个月,围术期未口服抗凝药组患者的IPSS评分较围术期口服抗凝药组患者低0.6分（MD=0.61,95%CI：0.19~1.04,P=0.005,I²=0）。两组患者在其他观察指标方面无明显统计学差异。结论：绿激光前列腺汽化术治疗围术期口服抗凝药的前列腺增生患者安全有效。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘巍
	魏世平
	李晓山

关键词 ：绿激光前列腺汽化术, 良性前列腺增生, 抗凝药

Abstract：Objective： To assess the effectiveness and safety of greenlight photoselective vaporization of the prostate （PVP） among the patients with benign prostate hyperplasia （BPH） on or off oral anticoagulation. Methods： Embase, Cochrane Library, WanFang Data, China National Knowledge Infrastructure （CNKI）. Newcastle-Ottawa Scale （NOS） was used to assess the quality and risk of bias of each study. Six parameters （operation time, catheterization time, hospitalization time, Q_max, IPSS and postvoid residual volume） from patients on or off anticoagulant therapy were collected. All statistical analyses were conducted with Revman V.5.3 software. Results： Totally, 993 patients from 7 studies were eventually included. There were no significant differences in prostate volume, Q_max, IPSS score and residual urine between the two groups. Perioperative operative time in oral anticoagulants group was longer than that of non-oral anticoagulants group, but the difference was not statistically significant. Meanwhile, IPSS in non-anticoagulants group was significantly reduced by 0.6 as compared with that in anticoagulants group at 3rd month postoperation [MD 0.61, 95% CI （0.19 - 1.04）, P = 0.005, I² = 0]. However, there was no significant difference in other parameters. Conclusion： PVP is an effective and safe option for BPH patients on or off oral anticoagulants.

Key words： greenlight photoselectibe vaporization of the prostate benign prostate hyperplasia anticoagulation

收稿日期: 2020-09-11

通讯作者: 李晓山,1263362910@qq.com

引用本文:

刘巍, 魏世平, 李晓山. 绿激光前列腺汽化术治疗围术期口服抗凝药患者疗效与安全性的Meta分析[J]. 微创泌尿外科杂志, 2021, 10(3): 195-201.
LIU Wei, WEI Shiping, LI Xiaoshan. Effectiveness and Safety of Greenlight Photoselective Vaporization of the Prostate in Patients on Ongoing Oral Anticoagulation: A Meta Analysis. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2021, 10(3): 195-201.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1681.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2021/V10/I3/195

[1] MADERSBACHER S, SAMPSON N, CULIG Z.Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a Mini-Review. Gerontology, 2019,65(5):458-464.
[2] OELKE M, BACHMANN A, DESCAZEAUD AA, et al.EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013,64(1):118-140.
[3] AL-RAWASHDAH SF, PASTORE AL, SALHI YA, et al.Prospective randomized study comparing monopolar with bipolar transurethral resection of prostate in benign prostatic obstruction: 36-month outcomes. World J Urol, 2017,35(10):1595-1601.
[4] KUSLJIC S, ANEJA J, MANIAS E.Incidence of complications in men undergoing transurethral resection of the prostate. Collegian, 2017,24(1):3-9.
[5] GUO R, YU W, MENG Y, et al.Correlation of ASA grade and the charlson comorbidity index with complications in patients after transurethral resection of prostate. Urology, 2016,98:120-125.
[6] EKEN A, SOYUPAK B, ACIL M, et al.Safety, efficacy and outcomes of the new GreenLight XPS 180W laser system compared to the GreenLight HPS 120W system for the treatment of benign prostatic hyperplasia in a prospective nonrandomized single-centre study. Can Urol Assoc J, 2015,9(1/2):e56-e60.
[7] LUO F, SUN HH, SU YH, et al.GreenLight laser photoselective vaporization of the prostate for treatment of benign prostate hyperplasia/lower urinary tract symptoms in patients with different post-void residual urine. Lasers Med Sci, 2017,32(4):895-901.
[8] DAELS F, GAIZAUSKAS A, RIOJA JA, et al.Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study. World J Urol, 2015,33(6):859-864.
[9] SOHN JH, CHOI YS, KIM SJ, et al.Effectiveness and safety of photoselective vaporization of the prostate with the 120 W HPS greenlight laser in benign prostatic hyperplasia patients taking oral anticoagulants. Korean J Urol, 2011,52(3):178-183.
[10] PIOTROWICZ G, SYRYŁO T, JEDYNAK R, et al. Efficacy and safety of photoselective vaporization of the prostate with 120 W 532 nm laser in patients with benign prostatic hyperplasia on anticoagulation or antiplatelet therapy: observations on Long-Term outcomes. Photomed Laser Surg, 2018,36(5):273-283.
[11] RUSZAT R, WYLER S, FORSTER T, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol, 2007,51(4):1031-1038; discussion 1038-1041.
[12] HORI Y, KUROMATSU I, SUGIMURA Y.Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients with oral anticoagulant therapy. Hinyokika Kiyo, 2008,54(10):651-656.
[13] 周松林,单玉喜.高功率绿激光治疗口服抗凝药前列腺增生患者的疗效及安全性.中华腔镜泌尿外科杂志(电子版),2015,9(1):48-51.
[14] 唐飞,陈立军,赵立,等.选择性120W绿激光汽化术治疗正在口服抗凝药物良性前列腺增生症的临床观察.临床外科杂志,2012,20(10):743-745.
[15] 雒向宁,王禾,杨波.选择性绿激光前列腺汽化术患者围手术期维持口服抗凝药的安全性与手术效果探讨.中国现代医学杂志,2012,22(15):84-87.
[16] STANG A.Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010,25(9):603-605.
[17] 吕学锋,郭强,李双平,等.抗栓药物对良性前列腺增生手术围术期出血影响的Meta分析.现代泌尿外科杂志,2019,24(5):369-376.
[18] RÜHLE A, BLARER J, OEHME F, et al. Safety and effectiveness of bipolar transurethral resection of the prostate in patients under ongoing oral anticoagulation with coumarins or antiplatelet drug therapy compared to patients without anticoagulation/antiplatelet therapy. J Endourol, 2019,33(6):455-462.
[19] YAN Z, XUE BX, NADEEM AM.Greenlight high-performance sustem(HPS)120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. Lasers Med Sci, 2016,31(3):485-495.
[20] MESKAWI M, HUEBER PA, VALDIVIESO R, et al.Complications and functional outcomes of high-risk patient with cardiovascular disease on antithrombotic medication treated with the 532-nm-laser photo-vaporization Greenlight XPS-180 W for benign prostate hyperplasia. World J Urol, 2019,37(8):1671-1678.
[21] SHAO IH, HOU CP, CHEN SM, et al.The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia. Clin Interv Aging, 2013,8:265-269.
[22] HUET R, MATHIEU R, ROHOU T, et al.MRI assessment of tissue effects after 180-W XPS greenlight laser vaporization of the prostate. Lasers Surg Med, 2017,49(6):577-581.
[23] LEE DJ, RIEKEN M, HALPERN J, et al.Laser vaporization of the prostate with the 180-W XPS-Greenlight laser in patients with ongoing platelet aggregation inhibition and oral anticoagulation. Urology, 2016,91:167-173.
[24] 盛烨华,滕竞飞,艾星,等.高功率绿激光汽化切除术与经尿道前列腺电切术治疗良性前列腺增生症的疗效比较.微创泌尿外科杂志,2018,7(6):414-417.
[25] 陈金虎,张贤生,张翼飞,等.绿激光前列腺汽化术在口服抗凝药物前列腺增生患者中的应用.临床泌尿外科杂志,2019,34(10):804-808.
[26] LAW KW, ELTERMAN DS, CASH H, et al.Anatomic GreenLight laser vaporization-incision technique for benign prostatic hyperplasia using the XPS LBO-180W system: How I do it. Can J Urol, 2019,26(5):9963-9972.
[27] SUN J, SHI A, TONG Z, et al.Green light photoselective vaporization of the prostate: a safe and effective treatment for elderly high-risk benign prostate hyperplasia patients with gland over 80 ml. Lasers Med Sci, 2018,33(8):1693-1698.